Ricerca avanzata
Accedi
Accedi
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrazione
Registrazione via e-mail
Oppure accedi con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Home
  2. Azioni
  3. Stati Uniti
  4. Nyse
  5. Cybin Inc.
  6. Notizie
  7. Altre lingue
    CYBN   CA23256X1006

CYBIN INC.

(CYBN)
  Rapporto
Tempo differito Nyse  -  21:59 28/09/2022
0.4969 USD   -3.85%
27/09Mindset Pharma Inc. fornisce una licenza strategica di proprietà intellettuale a Cybin Inc.
CI
20/09Cybin raggiunge le pietre miliari della ricerca e dello sviluppo in anticipo rispetto alle tempistiche previste.
CI
30/08Cybin dichiara che sono stati somministrati i primi due pazienti nella sperimentazione di CYB003 per il trattamento della depressione.
MT
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivatiFondi 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su CYBIN INC.
27/09Mindset Pharma Provides Strategic Intellectual Property License to NYSE-listed Cybin
27/09Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
27/09Mindset Pharma Provides Strategic Intellectual Property License to Cybin
27/09Mindset Pharma Inc. Provides Strategic Intellectual Property License to Cybin Inc
21/09Cybin to Participate in Upcoming Scientific and Investor Conferences
20/09Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
20/09Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
31/08Cybin Announces Final Adelia Milestone Achievement
30/08Cybin Says First Two Patients Dosed in Trial of CYB003 to Treat Depression
30/08Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the..
30/08Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the..
25/08Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
17/08Cybin: and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human ..
17/08Cybin, Clinilabs Says DEA Grants it Schedule 1 License for CYB003 to Treat Major Depres..
17/08Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human..
17/08Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement A..
16/08Cybin: Corporate Presentation - August 2022
16/08Cybin: Announces Results of Shareholders' Meeting - Form 6-K
16/08Cybin Announces Results of Shareholders Meeting
15/08Cybin Announces Results of Shareholders' Meeting
11/08Transcript : Cybin Inc. Presents at Canaccord Genuity 42nd Annual Growth Conf..
10/08Cybin: CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity..
09/08Cybin: EXPLANATORY NOTE - Form 6-K/A
09/08Cybin: CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED - F..
09/08Cybin: ANNOUNCES UP TO USD$35 MILLION AT-THE-MARKET EQUITY PROGRAM - Form 6-K
09/08Cybin: INCORPORATION BY REFERENCE - Form 6-K/A
08/08CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Prog..
08/08Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
08/08Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022
28/07Cybin: to Present at the Canaccord Genuity 42nd Annual Growth Conference - Form 6-K
28/07Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
25/07Cybin: Announces Date of Annual Meeting of Shareholders - Form 6-K
25/07Cybin: NOTICE OF ANNUAL MEETING OF SHAREHOLDERS - Form 6-K
25/07Cybin Announces Date of Annual Meeting of Shareholders
22/07Cybin: Amendment to Annual Report by Canadian Issuer - Form 40-F/A
12/07Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluatin..
12/07Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase..
11/07Cybin: Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical - Form 6-K
11/07Cybin Completes Acquisition of DMT Study From Entheon
11/07Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
28/06Cybin Announces Additional Adelia Milestone Achievement
27/06Cybin: Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for..
27/06Cybin Gets FDA Approval to Proceed With Study of CYB003 for Major Depressive Disorder; ..
27/06Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 fo..
27/06Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb0..
23/06Cybin Inc. - Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
22/06Cybin: Annual Report by Canadian Issuer (Form 40-F)
22/06Cybin: Reports Fiscal Year 2022 Financial Results and Recent Business Highlights - Form 6..
22/06Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
22/06Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2022
22/06Cybin Inc. Auditor Raises 'Going Concern' Doubt
16/06Cybin: to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, ..
16/06Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27,..
10/06Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
10/06Sector Update: Health Care
09/06Cybin: Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Eva..
09/06Cybin Gets Review Board Nod to Start Trial in Major Depressive Disorder; Stock Up Over ..
09/06Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Ev..
09/06Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Ev..
09/06Transcript : Cybin Inc. - Special Call
07/06Cybin: Acquires DMT Clinical Study from Entheon Biomedical - Form 6-K
07/06Cybin to Buy Clinical Trial From Entheon Biomedical to Advance Development of CYB004
07/06Cybin Acquires DMT Clinical Study from Entheon Biomedical
07/06Cybin Acquires DMT Clinical Study from Entheon Biomedical
06/06Cybin: Announces Additional Adelia Milestone Achievements - Form 6-K
06/06Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Fac..
04/06Cybin Announces Additional Adelia Milestone Achievements
03/06Cybin: Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Faci..
03/06Cybin: Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an In..
03/06Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Fac..
02/06Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an I..
02/06Cybin to Host Key Opinion Leader Webinar on June 9, 2022
31/05Cybin: Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 f..
31/05Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CY..
31/05Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 ..
18/05Cybin to Participate in NYSE Trading Bell Ceremony
17/05Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
11/05Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
09/05Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measu..
09/05Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measur..
06/05Cybin Announces CYB003 Poster to be presented at the 'From Research to Reality' Global ..
05/05Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality' G..
05/05Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Realit..
28/04Cybin: Corporate Presentation – May 2022
22/04Cybin: to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2..
22/04Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, ..
21/04Cybin: Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluati..
21/04Cybin to Work With Clinilabs on Major Depressive Disorder Treatment Trial
21/04Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluat..
21/04Cybin Inc. Partners with Clinilabs Drug Development Corporation for Phase 1/2A Trial Ev..
13/04Cybin: Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intraveno..
13/04Cybin Says Preclinical Data Show Inhalation More Viable Administration Method for Anxie..
13/04Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intraven..
13/04Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Int..
08/04Cybin: Announces Publication of International PCT Patent Application for Inhalation Deliv..
08/04Cybin Announces Publication of International PCT Patent Application for Inhalation Deli..
06/04Cybin: to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2..
06/04Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, ..
04/04Cybin: Corporate Presentation – April 2022
01/04Cybin: Announces Additional Adelia Milestone Achievement - Form 6-K
Prossimo evento su CYBIN INC.
06/10/22Cantor Neurology & Psychiatry Conference
Prossimi eventi del settore
27/10/22GILEAD SCIENCES, INC. : Q3 2022 Pubblicazione dei risultati (proiezione)
02/11/22VERTEX PHARMACEUTICALS INCORPORATED : Q3 2022 Pubblicazione dei risultati (proiezione)
03/11/22WUXI APPTEC CO., LTD. : Q3 2022 Pubblicazione dei risultati (proiezione)
07/11/22BIONTECH SE : Q3 2022 Pubblicazione dei risultati
Settore
Sanitą
Biotecnologia/Farmaceutici
 Biotecnologia e ricerca medica
  Biotecnologia
   Farmaci bioterapeutici